Navigation Links
Imaging agents predict breast cancer response to endocrine therapy

Reston, Va. (July 2, 2012) Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen receptor-α (ERα) status is an important factor in determining the most appropriate treatment for breast cancer patients, especially for those who are ERα+ and likely to respond well to hormone-based, or endocrine, therapies.

Prominent professor and research chemist Michael J. Welch, PhD, who passed away in May, was a contributing author for this research. "Throughout his career, Dr. Welch specialized in the synthesis of new radiolabeled compounds for medical imaging, with a special emphasis on the growing numbers of applications in PET," said Dominique Delbeke, MD, PhD, editor of The Journal of Nuclear Medicine. Noted for his ability to see beyond the immediate aspects of basic work to potential future applications, Welch was both a prime mover and an integral part in the development of PET as it transitioned from a compelling investigative idea to widespread clinical acceptance. "Many of his discoveries and research will live on well into the future," said Delbeke.

The study, "Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer" was an example of his unique approach to research.

"Positron emission tomography, or PET, has typically been used to identify the target for endocrine therapy in breast cancer by demonstrating that ER is present in tumors using F-18-fluoroestradiol (FES)-PET, or by monitoring for hormone-induced changes in tumor metabolism'metabolic flare' with F-18-fluorodeoxyglucose (FDG)-PET once therapy has begun. What is novel about our study is that we chose to image progesterone receptor levels to see how the estrogen signaling pathway is functioning in response to endocrine therapy," said Amy Fowler, MD, PhD, lead author of the study.

In the study, mice with mammary cell lines (SSM1, SSM2 and SSM3) derived from STAT1-deficient mammary tumorswhich are ERα+/PR+ and similar to the majority of human breast cancerswere imaged. Small-animal PET/computed tomography (CT) was performed using F-18-FES to image estrogen receptor status, F-18-fluoro furanyl norprogesterone (F-18-FFNP) for progesterone receptor status, and FDG for glucose uptake.

Initial imaging of the cell lines showed that SSM3 tumors displayed the greatest F-18-FES and F-18-FFNP uptake, and therefore, the SSM3 cell line was used to test the response to estradiol, an ER agonist, and fulvestrant, a pure ER antagonist. Upon treatment with estradiol, it was determined that PR expression is estrogen-inducible and indicative of ERα signaling in the SSM3 tumors. Mice treated with fulvestrant showed early decreases in F-18-FFNP uptake after initiation of therapy, prior to measurable growth inhibition. SSM2 tumors, which were not growth-inhibited by fulvestrant despite also being ERα+/PR+, showed no change in F-18-FFNP uptake after initiation of therapy. These data support the potential use of PR imaging with F-18-FFNP PET of patients with ERα+ breast cancer at baseline and shortly after initiation of endocrine therapy to distinguish between responders and nonresponders, and thus help facilitate the selection of therapies most appropriate for individual patients.

"An important goal of molecular imaging in cancer research is to noninvasively predict early responses to therapies in order to guide further management," noted Fowler. "Our work using a preclinical model of breast cancer helps support the notion that molecular imaging can achieve this goal by testing whether the target utilized for a specific therapy is not only present but also functional."

An estimated one in eight women will develop breast cancer in her lifetime. According to the American Cancer Society, an estimated 280,000 new cases of breast cancer were diagnosed among women in 2011, and nearly 40,000 died from the disease.


Contact: Susan Martonik
Society of Nuclear Medicine

Related medicine news :

1. Mount Sinai is first in New York state to perform new Alzheimers imaging test in clinical setting
2. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
3. Fox Chase researchers find no disparities in imaging before breast cancer surgery
4. Study examines necessity of additional imaging in PET/CT oncologic reports
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
7. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
8. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Greater L.A. Heating Up, Climate Experts Predict
11. Blood test for pregnant women could predict risk of having dangerously small babies
Post Your Comments:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
Breaking Medicine Technology: